The BCG Vaccine is a vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.
At the recent 2021 Annual Scientific Sessions of the American Diabetes Association, researchers from Massachusetts General Hospital (MGH) presented positive updates on their trials of the bacillus Calmette-Guérin (BCG) vaccine to safely and significantly lower blood sugars.
An Australian-led study will investigate whether it's possible to predict who remains susceptible to SARS-CoV-2 variants after having COVID-19 or receiving a COVID-19-specific vaccine.
Varying immune response to vaccinations could be countered with microbiota-targeted interventions helping infants, older people and others to take full advantage of the benefits of effective vaccines, Australian and US experts say.
A considerably higher dose of the anti-tuberculosis drug rifampicin is safe and can also lead to a shorter treatment for tuberculosis and less resistance.
St Petersburg University scientists have analyzed about 100 academic papers and statistics on the incidence of COVID-19 in different countries of the world.
Differences in the immune systems and better blood vessel health were among the factors protecting children from severe COVID-19, according to a new review.
Recently, researchers from the Monash University and Monash Medical Centre, Clayton, Victoria, Australia, investigated whether peptide sensitization using BCG can produce cross-reactive T cells specific to SARS-CoV-2. Their study is published on the preprint server, medRxiv.
COVID-19 continues to wreak havoc globally, with over one million deaths to date. Yet what if an existing vaccine could make COVID-19 less deadly? A study just published put the theory to test, with promising results.
Researchers from Mayo Clinic, United States of America, have reviewed the immunity developed against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease.
A largescale global trial designed to test the theory that the widely-used BCG vaccine could help protect against COVID-19 will soon recruit healthcare staff and care home workers in the UK.
While scientists race to develop and test a vaccine effective against SARS-CoV-2, the virus that causes COVID-19, recent studies have indicated that countries with widespread BCG vaccination appear to be weathering the pandemic better than their counterparts.
In a new study published on the preprint server medRxiv, researchers from Laval University and McGill University in Canada reviewed evidence from 18 relevant studies on a possible interaction between influenza vaccines on non-influenza respiratory disease (NIRD).
The BCG vaccine has a broad, stimulating effect on the immune system. This gives it an effective preventive action against various infections - possibly also against COVID-19. New studies are investigating that.
. A new study explores whether and how the practice of routine BCG vaccination of infants may have curbed the initial spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Japan. The research is published in the Journal of Infection.
A tuberculosis vaccine administered during the past 15 years is associated with significantly improved COVID-19 outcomes, according to a new study published in Vaccines.
The BCG vaccine, a vaccine originally made against tuberculosis, has a general stimulating effect on the immune system and is therefore effective against multiple infectious diseases - possibly also against COVID-19.
In a recent medRxiv preprint research paper, scientists from India analyzed twenty European countries and showed that the prevalence of exposure to Mycobacterium spp. (which includes BCG vaccine) is consistently negatively correlated with coronavirus disease (COVID-19) infections.
One of the emerging questions about the coronavirus that scientists are working to understand is why developing countries are showing markedly lower rates of mortality in COVID-19 cases than expected.
A tuberculosis vaccine developed 100 years ago also makes vaccinated persons less susceptible to other infections. While this effect has been recognized for a long time, it is not known what causes it.
As the world grapples with the coronavirus disease (COVID-19) pandemic, scientists race to develop an effective vaccine to protect against the deadly SARS-CoV-2 virus. While potential vaccines are still being developed and tested, researchers propose that existing vaccines could give the immune system a temporary boost to ward off infection.